| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a24061629374fff17d3340b70f03bbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e26ecb049e4589370f2135488e794f04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eaa325bc97bdbbffac2295984da03f8f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d83fb19c0ef910ec433726a6d03e00a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_19651a3acf4d2f770bc157f414656e89 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-168
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1761 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-33 |
| filingDate |
2011-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71dd858b38862db506d92ac2247782b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77a31141d2e98d33d8dcaec1394c2a04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b2f677f32f538fd0b8a6fa4a24171393
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d983f2084174d1d8e01241720a457742
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_827a5746d4e2c6c2639ff5bcf671f9cc |
| publicationDate |
2015-10-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9168243-B2 |
| titleOfInvention |
Pharmaceutical compositions comprising 8-substituted dibenzylbutyrolactone lignans |
| abstract |
Therapeutic compositions comprising at least one 8-substituted-dibenzylbutyrolactone lignan, preferably a lignan is selected from the group of nortrachelogenin, diasteromeric forms of nortrachelogenin, isomeric forms of nortrachelogenin and combinations thereof as well as 8-methylmatairesinol and 8-methyldimethylmatairesinol, for use in a method of treating cancer or a similar condition wherein the growth factor signaling pathway of a mammal is deregulated. The invention also provides therapeutic pharmaceutical combinations comprising a hydroxy-dibenzylbutyrolactone lignan and at least one TRAIL receptor agonist. The hydroxy-dibenzylbutyrolactone lignans and a TRAIL receptor agonist can be used as a combined preparation for administration to a patient simultaneously, separately or spaced out over a period of time in treating cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2016120937-A1 |
| priorityDate |
2010-12-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |